Royalty Pharma EVP Christopher Hite Sells $5.85M in Class A Shares Under 10b5-1 Plan

Executive Insider Sale Summary: Royalty Pharma plc ($RPRX)

Transaction Overview

On September 22, 2026, Christopher Hite, Executive Vice President & Chairman, Partnering at Royalty Pharma plc, executed sales totaling 100,000 Class A Ordinary Shares across two transactions for an aggregate value of approximately $5.85 million.

• Tranche 1: 96,073 shares sold at a weighted average price of $58.5148 (range: $57.88 – $58.87).
• Tranche 2: 3,927 shares sold at a weighted average price of $58.9261 (range: $58.88 – $59.00).
• Combined Average Realized Price: ~$58.53 per share.

Context & 10b5-1 Trading Plan

Both transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on March 20, 2026. The adoption of this plan provides negative assurance regarding potential material non-public information influence, indicating scheduled liquidity rather than discretionary market timing.

Ownership & Holdings Structure

• The disposed shares were held indirectly through SCH Investment Partners LLC.
• Following the sale, SCH Investment Partners LLC holds 270,401 Class A Ordinary Shares.
• In addition, Mr. Hite directly retains 23,200 Class A Ordinary Shares.
• Per the filing remarks, family vehicles controlled by Mr. Hite also retain substantial economic exposure, holding partnership interests exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares exchangeable into 1,238,789 Class A Ordinary Shares (subject to vesting).

Market & Investor Takeaways

While the headline transaction value is sizable at ~$5.85M, the execution under an established Rule 10b5-1 trading plan combined with Mr. Hite's significant remaining direct and indirect holdings moderates the market impact.